OGN
Organon & Co.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+25/100
Last price
13.74
▲ 0.04 (0.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.74
Prev close
13.70
Day high
13.75
Day low
13.73
Volume
1.95M
Market cap
$3.61B
P/E (TTM)
17.62
52W range
5.69 – 13.79
Day trading desk
Gap from prior close
+0.29%
Prior close 13.70
VWAP
13.74
-0.00% from price
Relative volume
1.36×
Normal
Session range
0.15%
13.73 – 13.75
Position in range
50%
Mid range
ATR (14D)
0.04
0.30% of price
Prior day high
13.75
PDH
Prior day low
13.70
PDL
Bid / ask spread
—
Quote not published
Session volume
3.64M
Avg 2.68M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
-0.29%
-1.4%
3M
+2.00%
-2.5%
6M
+124.51%
+106.3%
YTD
+91.63%
+77.4%
1Y
+24.80%
+8.4%
3Y
-20.85%
-103.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on OGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-3.24K
Net selling
Buy transactions
2
37.97K shares
Sell transactions
2
41.21K shares
Net transactions
+4
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
1.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | ARJONA FERREIRA JUAN CAMILO Officer |
— | 11.52K | — | Direct |
| Aug 5, 26 | DRINANE JULIANA PAPA Officer |
SELL | 14.76K | $200.31K | Direct |
| May 6, 26 | HOLZBAUR LYNETTE Officer |
SELL | 26.45K | $353.08K | Direct |
| May 6, 26 | HOLZBAUR LYNETTE Officer |
BUY | 26.45K | $353.08K | Direct |
| Mar 31, 26 | WALSH MATTHEW M Chief Financial Officer |
— | 33.59K | — | Direct |
| Mar 31, 26 | ARJONA FERREIRA JUAN CAMILO Officer |
— | 13.43K | — | Direct |
| Mar 31, 26 | KARP DANIEL Officer |
— | 18.05K | — | Direct |
| Mar 31, 26 | STAHLER RACHEL A Chief Technology Officer |
— | 18.87K | — | Direct |
| Mar 31, 26 | WEAVER KIRKE General Counsel |
— | 18.51K | — | Direct |
| Mar 31, 26 | HOLZBAUR LYNETTE Officer |
— | 10.97K | — | Direct |
| Mar 31, 26 | DRINANE JULIANA PAPA Officer |
— | 16.45K | — | Direct |
| Mar 31, 26 | FALCIONE AARON Officer |
— | 17.93K | — | Direct |
| Mar 31, 26 | NISITA VITTORIO Officer |
— | 13.00K | — | Direct |
| Mar 31, 26 | MORRISSEY JOSEPH T JR Chief Executive Officer |
— | 24.58K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALI KEVIN |
Chief Executive Officer | 282.73K | Purchase |
COX CARRIE SMITH |
Officer and Director | — | Purchase |
DIMARCO KATHRYN |
Officer | 38.74K | Conversion of Exercise of derivative security |
FALCIONE AARON |
Officer | 101.43K | Conversion of Exercise of derivative security |
KARP DANIEL |
Officer | 69.55K | Conversion of Exercise of derivative security |
MORRISSEY JOSEPH T JR |
Chief Executive Officer | 123.12K | Conversion of Exercise of derivative security |
NISITA VITTORIO |
Officer | 70.62K | Conversion of Exercise of derivative security |
STAHLER RACHEL A |
Chief Technology Officer | 116.11K | Conversion of Exercise of derivative security |
WALSH MATTHEW M |
Chief Financial Officer | 212.75K | Conversion of Exercise of derivative security |
WEAVER KIRKE |
General Counsel | 92.64K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.61B
Enterprise value$11.03B
Revenue (TTM)$6.13B
Gross profit$3.27B
EBITDA$1.56B
Net income$209.00M
EPS (TTM)$0.78
Free cash flow$490.75M
Total cash$1.13B
Total debt$8.55B
Book value / share$3.83
Shares outstanding262.61M
Float242.99M
Short % of float7.59%
Dividend yield0.58%
Beta (5Y)1.54
Valuation & profitability ratios
Trailing P/E17.62
Forward P/E3.80
PEG ratio—
Price / sales—
Price / book3.59
EV / revenue1.80
EV / EBITDA7.05
Gross margin53.40%
Operating margin20.73%
Profit margin3.41%
Return on equity24.04%
Return on assets5.67%
Debt / equity850.20
Current ratio1.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.22B | $6.40B | $6.26B | $6.17B | -2.9% |
| Operating revenue | $6.22B | $6.40B | $6.26B | $6.17B | -2.9% |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | +8.0% |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | -10.8% |
| Research & development | $366.00M | $469.00M | $528.00M | $471.00M | -22.0% |
| Selling, general & admin | $1.72B | $1.76B | $1.89B | $1.70B | -2.2% |
| Total operating expense | $2.09B | $2.23B | $2.42B | $2.17B | -6.4% |
| Operating income | $1.23B | $1.49B | $1.33B | $1.71B | -17.5% |
| Net interest income | -$504.00M | -$520.00M | -$527.00M | -$422.00M | +3.1% |
| Pre-tax income | $425.00M | $807.00M | $673.00M | $1.12B | -47.3% |
| Tax provision | $238.00M | -$57.00M | -$350.00M | $205.00M | +517.5% |
| Net income | $187.00M | $864.00M | $1.02B | $917.00M | -78.4% |
| Net income to common | $187.00M | $864.00M | $1.02B | $917.00M | -78.4% |
| Basic EPS | 0.72 | 3.36 | 4.01 | 3.61 | -78.6% |
| Diluted EPS | 0.72 | 3.33 | 3.99 | 3.59 | -78.4% |
| EBIT | $929.00M | $1.33B | $1.20B | $1.54B | -30.0% |
| EBITDA | $1.29B | $1.60B | $1.44B | $1.76B | -19.6% |
| Basic shares | 259.50M | 257.05M | 255.24M | 254.08M | +1.0% |
| Diluted shares | 260.76M | 259.15M | 256.27M | 255.17M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $574.00M | $675.00M | $693.00M | $706.00M | -15.0% |
| Cash & short-term investments | $574.00M | $675.00M | $693.00M | $706.00M | -15.0% |
| Accounts receivable | $1.33B | $1.36B | $1.74B | $1.48B | -2.0% |
| Inventory | $1.41B | $1.32B | $1.31B | $1.00B | +6.4% |
| Total current assets | $4.35B | $4.35B | $4.51B | $3.93B | +0.1% |
| Property, plant & equipment | $1.30B | $1.17B | $1.18B | $1.02B | +11.6% |
| Goodwill & intangibles | $5.28B | $6.09B | $5.14B | $5.25B | -13.3% |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | -1.8% |
| Total current liabilities | $2.39B | $2.72B | $2.92B | $2.51B | -12.1% |
| Current debt | $16.00M | $20.00M | $9.00M | $8.00M | -20.0% |
| Long-term debt | $8.63B | $8.86B | $8.75B | $8.90B | -2.6% |
| Total debt | $8.64B | $8.88B | $8.76B | $8.91B | -2.7% |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | -4.1% |
| Retained earnings | $1.11B | $1.01B | $443.00M | -$331.00M | +9.8% |
| Shareholder equity | $752.00M | $472.00M | -$70.00M | -$892.00M | +59.3% |
| Working capital | $1.96B | $1.63B | $1.59B | $1.42B | +20.4% |
| Net tangible assets | -$4.53B | -$5.62B | -$5.21B | -$6.14B | +19.4% |
| Shares issued | 260.32M | 257.80M | 255.63M | 254.37M | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $187.00M | $864.00M | $1.02B | $917.00M | -78.4% |
| Depreciation & amortisation | $361.00M | $277.00M | $236.00M | $212.00M | +30.3% |
| Stock-based compensation | $77.00M | $105.00M | $101.00M | $75.00M | -26.7% |
| Change in working capital | -$247.00M | -$278.00M | -$155.00M | -$452.00M | +11.2% |
| Operating cash flow | $700.00M | $939.00M | $799.00M | $858.00M | -25.5% |
| Capital expenditure | -$316.00M | -$351.00M | -$261.00M | -$427.00M | +10.0% |
| Investing cash flow | -$390.00M | -$513.00M | -$260.00M | -$420.00M | +24.0% |
| Dividends paid | -$88.00M | -$297.00M | -$294.00M | -$290.00M | +70.4% |
| Financing cash flow | -$561.00M | -$368.00M | -$569.00M | -$433.00M | -52.4% |
| Free cash flow | $384.00M | $588.00M | $538.00M | $431.00M | -34.7% |
| End cash position | $574.00M | $675.00M | $693.00M | $706.00M | -15.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.56B | $1.46B | $1.51B | $1.60B | $1.59B | +6.7% |
| Operating revenue | $1.56B | $1.46B | $1.51B | $1.60B | $1.59B | +6.7% |
| Cost of revenue | $711.00M | $677.00M | $766.00M | $745.00M | $720.00M | +5.0% |
| Gross profit | $847.00M | $783.00M | $741.00M | $857.00M | $874.00M | +8.2% |
| Research & development | $90.00M | $93.00M | $91.00M | $84.00M | $95.00M | -3.2% |
| Selling, general & admin | $434.00M | $424.00M | $433.00M | $415.00M | $453.00M | +2.4% |
| Total operating expense | $524.00M | $517.00M | $524.00M | $499.00M | $548.00M | +1.4% |
| Operating income | $323.00M | $266.00M | $217.00M | $358.00M | $326.00M | +21.4% |
| Net interest income | -$108.00M | -$111.00M | -$121.00M | -$128.00M | -$131.00M | +2.7% |
| Pre-tax income | $183.00M | $213.00M | -$148.00M | $243.00M | $229.00M | -14.1% |
| Tax provision | $75.00M | $67.00M | $57.00M | $83.00M | $84.00M | +11.9% |
| Net income | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | -26.0% |
| Net income to common | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | -26.0% |
| Basic EPS | 0.41 | 0.56 | -0.79 | 0.61 | 0.56 | -26.8% |
| Diluted EPS | 0.40 | 0.55 | -0.79 | 0.61 | 0.56 | -27.3% |
| EBIT | $291.00M | $324.00M | -$27.00M | $371.00M | $360.00M | -10.2% |
| EBITDA | $371.00M | $410.00M | $69.00M | $463.00M | $449.00M | -9.5% |
| Basic shares | 262.61M | 260.37M | 260.17M | 259.98M | 259.94M | +0.9% |
| Diluted shares | 270.45M | 262.90M | 260.17M | 260.65M | 260.16M | +2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | +1.4% |
| Cash & short-term investments | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | +1.4% |
| Accounts receivable | $1.49B | $1.38B | $1.33B | $1.48B | $1.48B | +7.8% |
| Inventory | $1.35B | $1.37B | $1.41B | $1.49B | $1.45B | -1.6% |
| Total current assets | $5.11B | $4.93B | $4.35B | $4.70B | $4.62B | +3.6% |
| Property, plant & equipment | $1.28B | $1.28B | $1.30B | $1.29B | $1.27B | +0.2% |
| Goodwill & intangibles | $5.26B | $5.25B | $5.28B | $6.02B | $6.04B | +0.2% |
| Total assets | $13.18B | $13.00B | $12.87B | $13.55B | $13.50B | +1.4% |
| Total current liabilities | $2.62B | $2.50B | $2.39B | $2.68B | $2.80B | +4.6% |
| Current debt | $74.00M | $16.00M | $16.00M | $45.00M | $115.00M | +362.5% |
| Long-term debt | $8.48B | $8.55B | $8.63B | $8.78B | $8.78B | -0.9% |
| Total debt | $8.55B | $8.57B | $8.64B | $8.83B | $8.90B | -0.2% |
| Total liabilities | $12.17B | $12.09B | $12.12B | $12.65B | $12.77B | +0.7% |
| Retained earnings | $1.35B | $1.25B | $1.11B | $1.32B | $1.16B | +7.9% |
| Shareholder equity | $1.01B | $903.00M | $752.00M | $906.00M | $733.00M | +11.4% |
| Working capital | $2.50B | $2.43B | $1.96B | $2.02B | $1.82B | +2.6% |
| Net tangible assets | -$4.26B | -$4.35B | -$4.53B | -$5.11B | -$5.31B | +2.1% |
| Shares issued | 262.61M | 262.65M | 260.32M | 259.98M | 259.96M | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | -26.0% |
| Depreciation & amortisation | $80.00M | $86.00M | $96.00M | $92.00M | $89.00M | -7.0% |
| Stock-based compensation | $25.00M | $19.00M | $7.00M | $24.00M | $22.00M | +31.6% |
| Change in working capital | -$125.00M | $42.00M | -$34.00M | -$27.00M | -$61.00M | -397.6% |
| Operating cash flow | $107.00M | $225.00M | $141.00M | $264.00M | $220.00M | -52.4% |
| Capital expenditure | -$76.00M | -$47.00M | -$65.00M | -$115.00M | -$39.00M | -61.7% |
| Investing cash flow | -$76.00M | $386.00M | -$65.00M | -$115.00M | -$38.00M | -119.7% |
| Dividends paid | -$6.00M | -$5.00M | -$4.00M | -$3.00M | -$10.00M | -20.0% |
| Financing cash flow | -$12.00M | -$38.00M | -$187.00M | -$76.00M | -$223.00M | +68.4% |
| Free cash flow | $31.00M | $178.00M | $76.00M | $149.00M | $181.00M | -82.6% |
| End cash position | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | +1.4% |
Options analytics
Put / call volume
1.74
Put-heavy session
Put / call open interest
0.14
Positioning, not flow
Max pain
13.00
-5.4% from spot
ATM implied vol
15.6%
Nearest strike to spot
Skew (10% OTM)
-17.2%
Calls bid over puts
Call volume
78
Contracts, this expiry
Put volume
136
Contracts, this expiry
Heaviest call OI
14.00
6.26K contracts
Heaviest put OI
13.00
815 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.07 | 0.85 | -20.6% |
| Mar 2026 | 0.85 | 0.71 | -16.8% |
| Dec 2025 | 0.73 | 0.63 | -13.3% |
| Sep 2025 | 0.93 | 1.01 | +8.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.88 | 1 | $1.58B | -1.1% |
| Next quarter | 0.81 | 1 | $1.55B | +2.9% |
| Current year | 3.34 | 2 | $6.17B | -0.8% |
| Next year | 3.62 | 6 | $6.32B | +2.5% |
Analyst targets & ownership
Mean target$11.25
High target$14.00
Low target$8.00
Implied upside-18.12%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 0
Hold4
Sell / Strong sell0 / 1
Held by insiders0.46%
Held by institutions84.75%
Institutions holding788
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.72
+0.13% from price
SMA 20
13.69
+0.33% from price
SMA 50
13.68
+0.40% from price
SMA 100
13.57
+1.26% from price
SMA 200
10.96
+25.40% from price
EMA 12
13.71
+0.18% from price
EMA 26
13.70
+0.26% from price
EMA 50
13.61
+0.97% from price
RSI (14)
58.1
Neutral
MACD (12,26,9)
0.01
Hist -0.00
ATR (14)
0.04
0.30% of price
Realised vol 30D
2.7%
Annualised
Bollinger upper
13.76
20, 2σ
Bollinger lower
13.63
20, 2σ
50 / 200 cross
Golden
13.68 vs 10.96
Trend bias
Above 200
+25.40%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.65
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
2.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-47.4%
Peak to trough
Max drawdown 5Y
-85.5%
Peak to trough
ATR 14
0.04
0.30% of price
Beta (reported)
1.54
5Y monthly, from filing
Short interest
Shares short
17.53M
Prior 15.14M
Change vs prior
+15.8%
Shorts adding
% of float
7.59%
Normal
% of shares out
6.68%
Against total outstanding
Days to cover
5.5
Crowded exit
Float
242.99M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 26 | BNP Paribas | DOWNGRADE | Outperform | Neutral |
| Apr 28, 26 | Piper Sandler | UPGRADE | Underweight | Neutral |
| Feb 24, 26 | Barclays | MAINTAINED | Underweight | Underweight |
| Dec 9, 25 | Barclays | INITIATED | — | Underweight |
| Nov 11, 25 | JP Morgan | MAINTAINED | Underweight | Underweight |
| Nov 11, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 15, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 5, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 9, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Feb 14, 25 | Barclays | MAINTAINED | Overweight | Overweight |
| Feb 14, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Sep 6, 24 | JP Morgan | DOWNGRADE | Neutral | Underweight |
Dividends & splits
Forward rate$0.08 / yr
Forward yield0.58%
5-year avg yield2.50%
Payout ratio10.26%
Ex-dividend dateAug 14, 2026
Next pay dateSep 10, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-17
Proxy Statements
DEFM14A · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-11
Proxy Statements
PREM14A · 2026-06-01
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-04
Headlines
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Zacks · 5d ago
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Business Wire · 6d ago
Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis
MT Newswires · 9d ago
Why Organon (OGN) Is Getting Attention Today
Simply Wall St. · 15d ago
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device
Simply Wall St. · 15d ago
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks · 16d ago
PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor
PR Newswire · 21d ago
Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review
MT Newswires · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.